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Background. Many statistical models have been tested to predict phenotypic or virological response from genotypic data. A
statistical framework called Super Learner has been introduced either to compare diﬀerent methods/learners (discrete Super
Learner) or to combine them in a Super Learner prediction method. Methods. The Jaguar trial is used to apply the Super Learner
framework. The Jaguar study is an “add-on” trial comparing the eﬃcacy of adding didanosine to an on-going failing regimen.
Our aim was also to investigate the impact on the use of diﬀerent cross-validation strategies and diﬀerent loss functions. Four
diﬀerent repartitions between training set and validations set were tested through two loss functions. Six statistical methods were
compared.WeassessperformancebyevaluatingR2 valuesandaccuracybycalculatingtheratesofpatientsbeingcorrectlyclassiﬁed.
Results. Our results indicated that the more recent Super Learner methodology of building a new predictor based on a weighted
combination of diﬀerent methods/learners provided good performance. A simple linear model provided similar results to those of
this new predictor. Slight discrepancy arises between the two loss functions investigated, and slight diﬀerence arises also between
results based on cross-validated risks and results from full dataset. The Super Learner methodology and linear model provided
around 80% of patients correctly classiﬁed. The diﬀerence between the lower and higher rates is around 10 percent. The number
of mutations retained in diﬀerent learners also varys from one to 41. Conclusions. The more recent Super Learner methodology
combining the prediction of many learners provided good performance on our small dataset.
1.Introduction
The eﬀectiveness of antiretroviral therapy has been limited
by the development of human immunodeﬁciency virus type
1 (HIV-1) drug resistance. HIV-1 frequently develops resis-
tance to the antiretroviral drugs used to treat it which
may decrease both the magnitude and the duration of the
response to treatment resulting in loss of viral suppression
and therapeutic failure [1]. Moreover, there is a high level of
cross-resistance within drug classes; a virus that has develop-
ed resistance to one drug in a class may also be resistant to
otherdrugsinthesameclass[2].CurrentInternationalAIDS
Society USA and French report HIV-1 guidelines recom-
mend resistance testing both before starting antiretroviral
therapy(ART)andattreatmentfailure.Resistancetestinghas
become an important part of choosing and optimizing com-
bination therapy for treating HIV-infected individuals [3].
Selecting a “salvage” regimen for an HIV-infected patient
who has developed resistance to his or her current regimen
is not straightforward [4].
Genotypic or phenotypic assays are used for resistance
testing each, assay having advantages and limitations. From
those assays we used either the genotypic-phenotypic corre-
lation, showing phenotypic eﬀect of mutations, or the geno-
typic-virologic correlation,investigating theimpactofmuta-
tions on the virological response to a subsequent treat-
ment. The latter correlation is mainly used by the Agence Na-
t i o n a l ed eR e c h e r c h e ss u rl eS I D At ob u i l dr u l e - b a s e da l g o -
rithms (ANRS http://www.hivfrenchresistance.org/). The2 AIDS Research and Treatment
increasing number of antiretroviral drug-resistance-asso-
ciated mutations has increased the diﬃculty of the interpre-
tation of those assays [5].
In both cases many HIV-1 drug resistance analysis ap-
proaches have been explored, from simple linear models [6]
to more sophisticated ones, such as database pattern search
method [7], neural networks/machine learning [8–11], or
genotype-phenotype mapping [12]. Such methods, or learn-
ers, diﬀer by the mechanism used to search over the space
of parameters. It appears that diﬀerent interpretation sys-
tems lead to distinct results [13–15]. Current widely used
genotypic interpretation systems may have no satisfactory
performance on newly derived datasets. Such poor perfor-
mancesemphasize theneedforanexternalvalidationdataset
or a suﬃcient large database to create a validation set. It has
been shown that the variability observed in diﬀerent rule-
based algorithms was mainly due to the patients’ baseline
characteristics than to the statistical methods used [16, 17].
A framework for the uniﬁed loss-based estimation sug-
gested a solution to this problem in the form of a new esti-
mator, called the “Super Learner” [18, 19]. Initially this
methodology, called Discrete Super Learner, compared dif-
ferent learners (methods) on the basis of the loss-based esti-
mation theory and choose the optimal learner for a given
predictionproblembasedoncross-validatedrisk(repartition
between training sample and validation sample) [20]. The
Super Learner methodology has been improved building
nowanestimatorbasedonalinearcombinationofthediﬀer-
ent learners investigated [19, 21, 22].
Originally, the Super Learner used both mean square of
residuals (diﬀerences between observed and predicted out-
comes) and R2 for evaluation and assessment. However, sta-
tistical investigations showed the importance of exploring
diﬀerent loss functions [23], such as ﬁrst-order coeﬃcient R.
Our aim is to study the performance of the discrete and
the most recent Super Learner methodology on a small sam-
pleofHIV-1datafromarandomizedclinicaltrial.Especially,
based on this methodology, we investigate four diﬀerent
cross-validation setting, and the use of two loss func-
tions for six statistical learning methods. This methodology
is applied on the Jaguar trial data [24].
2. Methods
2.1.Datasets. For a patient i,thedataconsistofavector Xi of
binaryvariablesindicatingpresenceorabsenceofamutation
and Yi denotes the virologic outcome. In the regression set-
ting, the objective is to predict Y using X. Then, the param-
eter of interest is denoted as E(Y|X). We analyzed the data
obtained from the Jaguar trial which are described elsewhere
[24]. Brieﬂy the Jaguar trial was a randomized multicenter,
double-blind placebo-controlled trial evaluating the eﬃcacy
of adding didanosine (ddI) to an on-going antiretroviral
(ARV) regimen. Patients were randomly assigned at a ratio
2:1 to receive ddI or a matching placebo added to their
current regimen. The primary eﬃcacy end point was the
magnitude of change in plasma HIV-1 RNA levels in log10
copiespermLfrombaselinetoweek4.Thena¨ ıvemethodwas
used to compute viral load reduction; that is, all HIV-1 RNA
levels<50copies/mLatweekfourwereﬁxedat50copies/mL.
Although censored methods are preferred to compute HIV-1
RNA changes, the low percentage (11%) of patients censored
providesinthiscaseanunbiasedestimate[25–27].Themed-
ian changes in HIV-1 RNA at week 4 were −0.56log10 cop-
ies/mL (IQR, −0.14 to −1.2) and +0.07log10 copies/mL
(IQR,0.12to0.21)inpatientsreceivingddIandplacebo,res-
pectively (P<. 0001). HIV-1 sequences were available for all
patients, but only patients in the ddI group were used in the
present work. HIV-1 sequences and HIV-1 RNA reduction
at week 4 were available for 102 patients. Mutations were
deﬁned as amino acid diﬀerences from subtype B consensus
wild-type sequence (wild-type virus HXB2). We investigate
the virologic impact at week 4 of ten resistance mutations:
M41L (prevalence 48%), D67N (34.3%), T69D (8.8%),
K70R (26.5%), L74V (8.8%), V118I (18.6%), M184VI
(92.2%), L210W (27.5%), T215Y/F (53.9%), and K219Q/E
(24.5%). This set has been the starting point for building
ANRS ddI rules and was potentially linked to the ddI resis-
tance at the time of the study. Moreover, the choice of using
a subset of mutations is driven by Soo Yon Rhee et al. study
[28], in which they show that expert mutation selection is
preferable than using the entire sequences.
2.2. Super Learner. The methodology has been proposed by
Mark van der Laan et al. [18, 19] as a setting to choose
the optimal learner (method) among a set of candidate
learners, this version of the methodology was called the
Discrete Super Learner. Recently, the methodology has been
reﬁned and proposed a new estimator based on a weighted
linear combination of candidate learners to build a Super
Learner estimator [19, 21, 22]. We brieﬂy introduced the
general principle and few key features of this methodology.
The general strategy for loss-based estimation is driven by
the choice of a loss function and relies on cross-validation
for estimator selection and performance assessment. Cross-
validation divides the available dataset into k mutually exclu-
sive and exhaustive sets of as nearly equal size as possible.
Each set and its complement play the role of the validation
and training samples. Observations in the training set are
used to construct (or train) the estimators, and observations
in the validation set are used to assess the performance (or
validate) of the estimators. For each estimator/learner the
k risks over the k validation sets are averaged resulting in
the so-called cross-validated risk. For example, with a 10-
fold cross-validation the learning set is partitioned into 10
parts, each part in turn served as a validation set, while the
other 9/10ths of the data served as the training set. Based
on cross-validated risks, estimators/learners can be ranked
from those identiﬁed as top learners to those providing poor
performance. In the discrete version of the methodology,
the optimal learner is applied to the entire dataset. In the
most recent version, a new estimator (the Super Learner)
is proposed based on a family of weighted combinations of
the estimators/learners. The new Super Learner appears as a
generalization of the discrete Super Learner.
We applied all individual learners and the new estimator
on full dataset (which will be called full model in the
following). Learners are ranked from those identiﬁed as topAIDS Research and Treatment 3
Table 1: Squared error, R detailed values and corresponding rank on Jaguar trial data for 10-fold, 4-fold, 3-fold, and 2-fold.
SqE without Logic Reg.
10-fold 4-fold 3-fold 2-fold
Method Rank Mean Rank Mean Rank Mean Rank Mean Mean rank
LM(1) 1.5 0.216 3 0.246 3 0.238 3 0.293 2.625
LM(2) 6 1.218 6 1.267 6 1.650 6 1.117 6
Random Forest 3 0.258 2 0.241 2 0.235 2 0.275 2.25
D/S/A 5 0.283 4 0.264 4 0.255 4 0.295 4.25
CART 4 0.264 5 0.267 5 0.258 5 0.298 4.75
Super Learner-5 1.5 0.216 1 0.238 1 0.228 1 0.273 1.125
1 −R without Logic Reg.
10-fold 4-fold 3-fold 2-fold
Method Rank Mean Rank Mean Rank Mean Rank Mean Mean rank
LM(1) 1.5 0.464 3 0.554 3 0.534 1.5 0.651 2.25
LM(2) 6 0.808 6 0.724 6 0.686 6 0.754 6
Random Forest 3 0.609 2 0.552 2 0.532 3 0.656 2.5
D/S/A 5 0.712 4 0.623 4 0.607 5 0.746 4.5
CART 4 0.632 5 0.644 5 0.611 4 0.743 4.5
Super Learner-5 1.5 0.464 1 0.539 1 0.508 1.5 0.651 1.25
learnerstothoseprovidingpoorperformance.Weinvestigate
foursplits:10-fold,4-fold,3-fold,and2-foldthatcorrespond
to 90%, 75%, 66%, and 50% of data use as training
samples and 10%, 25%, 33%, and 50% as validation sample
respectively.Learnerswereevaluatedusingtwodistinctfunc-
tions usually used as loss functions: squared error (SqE) and
ﬁrst-order coeﬃcient (R). The SqE is (Y −E(YX))
2, that
is, the squared diﬀerence between observed and predicted
outcome. R is the ﬁrst-order correlation coeﬃcient between
Y and E(Y|X), which has been recently used in this context
[29]. It is important to note that SqE is unbounded while
−1 ≤ R ≤ 1. For all full models, R2 estimates and accuracy
were also computed in addition to SqE and R.
Wedeﬁnedtwothresholdvaluestodeﬁnepatientshaving
a virologic response: −0.6log10 copies/mL and −0.5log10
copies/mL. For example, a patient with an HIV-1 RNA
r e d u c t i o nl a r g e rt h a n0 .6log10 copies/mL was classiﬁed as
responder, otherwise as nonresponder. Patients may also be
classiﬁedrespondersornotaccordingtothepredictedreduc-
tion by a given method.
3.CandidateLearners
Weinvestigatethefollowinglearners:LogicRegression,Dele-
tion/Substitution/Addition, Least squares regression, Ran-
dom Forest, Classiﬁcation and Regression Trees. All algo-
r i t h m sa r ea v a i l a b l ea sf r e ep a c k a g e so fR software.
Logic Regression (package named LogicReg) is an adap-
tive regression methodology that attempts to construct pre-
dictors as Boolean combinations of covariables [30]. Dele-
tion/Substitution/Addition (package named DSA) is polyno-
mial regression dataadaptive that generates candidate pre-
dictors as polynomial combinations of binary covariables
[31]. Classiﬁcation and Regression Trees (CARTs) build a re-
gression tree in continuous outcome setting (package rpart)
[32]. Random Forest (package RandomForest) is a “bagging
predictor” (Bootstrap Aggregating), this method build a
model from a combination of high number of regression
trees resulting in the so-called Forest [33]. Least squares reg-
ression was set up on two datasets: one consisted of all main
termsandthesecondconsistedofallmaintermsplusalltwo-
way interactions (resp. denoted as LM(1) and LM(2)).
From those learners, we set up two Super Learners: Super
Learner using ﬁve learners, built with D/S/A, LM(1), LM(2),
random forest and CART (noted Super Learner-5 in the fol-
lowing), and Super Learner with six learners, the same as
Super Learner-5 plus Logic Regression (denoted as Super
Learner-6 in the following).
Internal ﬁne-tuning procedure by internal cross-valida-
tion was used to obtain the best performance for Logic
Regression and D/S/A. The tuning parameters of D/S/A were
maxsize = 20 (two times the number of co-variables), max-
orderint = 2 and maxsumofpow = 2. All three steps were
allowed (Deletion, Substitution, and Addition). CART has
complexity parameter (cp) equal to 0.01. For Random Forest
the number of trees was 1,000 and the number of variables
to randomly consider at each node of each tree was ﬁxed at
three (mtry = 3). That corresponds to the number of co-vari-
ables divided by 3 which is usually used in regres-
sion setting. Simple linear regression was used as refer-
ence (without variable selection procedure). Methods were
ranked; if two or more methods produced the same risk
value, the mean rank was assigned (e.g., if Super Learner-5
and LM (1) gave the same SqE, in spite of assigning rank 1
and 2, resp., we noted 1.5 for both).
4. Results
Results of the Discrete Super Learner and Super Learner-5


























































function and a 10-fold cross-validation, LM(1) was identi-
ﬁed as the top learner followed by Random Forest and
CART. LM(1) slightly decreases its performance from the 1st
rank on 10-fold to 3th rank on 2-fold while Random Forest
becomes the second learners for the remaining k-folds. Sur-
prisingly, linear model with interaction terms, LM(2), pro-
vided poor performance for all k-fold. The Super Learner-5
p r o v i d e da tl e a s ta sg o o dp e r f o r m a n c ea st h et o pl e a r n e r
whatever the k-fold cross-validation. R loss function drew
similar ﬁndings. Although the ranks of the diﬀerent learn-
ers are relatively stable, the combination of the Super Learn-
er-5 provided the best performance. Inclusion of Logic
Reg as additional learner in the previous set of candi-
date learners led to diﬀerent ﬁndings (Table 2). Globally
Logic Reg performed poorly, and only LM(2) produced
worse performance than Logic Reg. Based on the SqE as
loss function, including Logic Reg in the Super Learner-6
decreased its performance compared to Super Learner-5.
Based on R as loss function, the performance of the Super
Learner-6 was very good.
We applied all learners including Super Learner-5 and
Super Learner-6 on the entire dataset (Table 3). Based on
SqE, R,a n dR2 measure estimates, Super Learner-5 and −6
provided very good performances. The use of LM(2) on
the full dataset provided a high level of prediction (R2 =
0.540)while,basedonk-foldcross-validatedrisk,thislearner
was the poorest candidate. Comparing cross-validation and
full model results indicate the LM(2) model was over ﬁt.
Figure 1 displays the mutations retained by each learner. All
mutations were retained for LM(1), LM(2), and Random
Forest(notsurprisinglyallmutationsareatleastselectedone
time in a tree). CART selected M41L, D67N, T69D, K70R,
L74V, and K219Q/E mutations. Of note the D/S/A method
selected only the M41L mutation which should be balanced
with its poor performance.
The ﬁnal goal of interpreting genotypic resistance testing
is to classify patients as “sensitive” or “resistant” to a
speciﬁc drug. Figure 2 displays the rates of patients being




















Figure 2: Rates of patients being well classiﬁed for threshold −0.5
and −0.6log10 for all models applied on the Jaguar trial full-dataset.
both threshold values LM(2), Super Learner-5 and −6h a v e
the highest accuracy with around 80% of patients correctly
classiﬁed. CART and Random Forest provided the lowest
accuracy, slightly below 70% of patients correctly classiﬁed,
corresponding to a 10% diﬀerence. As expected the accuracy
of Random Forest model depends on the mtry values.
5. Discussion
The choice of subsequent treatment in failing patients is of
major importance in the management of HIV-infected pa-
tients. Genotypic and phenotypic resistance tests are impor-
tant tools for choosing promising combination therapy for
those patients. We investigated on a small sample a frame-
work both for choosing optimal learner and building an
estimatoramongasetofcandidatethroughtwodiﬀerentloss
functions and k-fold cross-validation.
Based on cross-validation risk, the Super Learner estima-
tor was the “best” learner though the linear model with only
main terms LM(1) providing similar performance to that of
Super Learner-5 and -6. The use of the SqE as loss func-
tionindicatedthattheinclusionofLogicRegasanadditional
learner decreased the performance of the Super Learner esti-
mator. However, prediction results based on the full dataset
aswellasaccuracyquestionedtheuseofSqEaslossfunction,
although it is known that full dataset provided diﬀerent
results than those based on cross-validation strategy [34, 35].
Based on cross-validation risk, the good performance of
LM(1) should be compared with the poor performance of
the linear model with interaction terms LM(2). Inversely,
LM(2) outperforms LM(1) in the full dataset. In our small
dataset, this ﬁnding is clearly due to overﬁt of the data by
the LM(2) model. A researcher ignoring the Super Learner
methodology using a linear model with interaction terms
would obtain a good performance on the full dataset while
sucha learnerwouldhavenot been selected fromthediscrete
Super Learner methodology.
The choice of mtry parameter for Random Forest is a
real problem. However, the common mtry used in regression
setting (number of covariables divided by three) appears as a
good compromise. Whatever the mtry value is, all mutations
were selected at least on time using Random Forest on fullAIDS Research and Treatment 5
Table 2: Squared error, R detailed values and corresponding rank on Jaguar trial data for 10-fold, 4-fold, 3-fold, and 2-fold.
SqE with Logic Reg.
10-fold 4-fold 3-fold 2-fold
Method Rank Mean Rank Mean Rank Mean Rank Mean Mean rank
LM(1) 1 0.216 2 0.246 2 0.238 2 0.293 1.75
LM(2) 7 1.218 7 1.267 7 1.650 7 1.117 7
Random Forest 2 0.258 1 0.241 1 0.235 1 0.275 1.25
D/S/A 4 0.283 3 0.264 3 0.255 3 0.295 3.25
CART 3 0.264 4 0.267 4 0.258 4 0.298 3.75
LogicReg 6 0.653 6 0.65 6 0.652 6 0.653 6
Super Learner-6 5 0.378 5 0.455 5 0.499 5 0.527 5
1 −R with Logic Reg.
10-fold 4-fold 3-fold 2-fold
Method Rank Mean Rank Mean Rank Mean Rank Mean Mean rank
LM(1) 1.5 0.464 3 0.554 3 0.534 2 0.651 2.375
LM(2) 7 0.808 7 0.724 7 0.686 7 0.754 7
Random Forest 3 0.609 2 0.552 2 0.532 3 0.656 2.5
D/S/A 6 0.712 4 0.623 4 0.607 6 0.746 5
CART 4 0.632 5 0.644 5 0.611 5 0.743 4.75
LogicReg 5 0.702 6 0.685 6 0.684 4 0.657 5.25
Super Learner-6 1.5 0.456 1 0.523 1 0.485 1 0.593 1.125
Table 3: Squared Error, R, R2 and corresponding rank on Jaguar
Trial full-dataset.
Full Model SqE 1 −R/100 R2
Method Rank Value Rank Value Rank Value
LM (1) 5 0.204 5 0.435 4 0.319
LM (2) 1.5 0.138 1.5 0.265 1.5 0.540
Random Forest 4 0.178 4 0.348 6 0.271
D/S/A 7 0.242 7 0.561 7 0.193
CART 6 0.211 6 0.454 5 0.299
Super Learner-5 1.5 0.138 1.5 0.265 1.5 0.540
Super Learner-6 3 0.139 3 0.266 3 0.539
dataset. This was expected due to the relative small number
of mutations compared with 1,000 trees generated by the
Random Forest model
The HIV-1 resistance study used either a continuous
outcome (as HIV-1 RNA reduction from baseline to the time
of interest) or a categorical outcome (classifying patients as
achieving a virologic response at the time of interest). For
example, virologic response can be deﬁned an HIV-1 reduc-
tion of 1.5log10 copies/mL or more or having a viral load
>50 copies/mL at the time of interest. Even if a continuous
outcome is preferable as being more informative, the ﬁnal
goal of determining the drug resistance mutations associated
with a poorer virologic response is to classify patients as
“sensible” or “resistant” to a speciﬁed drug. The former
patients would receive the corresponding drug as a part of
their regimen while the latter patients would not. We used
two threshold values of −0.5a n d−0.6log10 copies/mL to
deﬁne virologic response. For both threshold values LM(2),
Super Learner-5 and -6 provided the highest accuracy with
approximately 80% of patients correctly classiﬁed.
All the methods used in this work are usually applied to
large or very large datasets. Simple linear regression model
was ﬁtted on more than 5,000 genotype-phenotype paired
datasets from the same database [6]. Investigation of logistic
regression and nonlinear machine learning for predicting
response to antiretroviral treatment was done on more than
3,000 treatment change episodes from the EuResist database
[34]. All these analyses were made retrospectively mainly for
comparing diﬀerent methods rather than for building rule-
based algorithm.
A major reason to apply the Super Learner methodology
on the Jaguar trial is that often the ﬁrst version of an algo-
rithm for a speciﬁc drug is based on a limited amount of data
[35–37]. Such algorithms are updated later with publication
of new data. Nonparametric methods are then often used
on such a relative small amount of data [38, 39]. Parametric
methods have the advantage of not only integrating two-way
interactionstermsbutalsoadjustingforsomeothervariables
that improve the prediction. Randomized clinical trials, in
treatment experienced patients, provide frequently the ﬁrst
opportunity to investigate the impact of baseline mutations
in the subsequent virologic response in those patients. It was
then of interest to know whether the Super Learner meth-
odology applied onlyonaroundone hundredofpatients was
able to produce the “best” learner on the basis of accuracy
and prediction. The Jaguar trial which is an “add-on” study
ensuring a good quality of relation between reverse trans-
criptase mutations and eﬀect on the drug investigated, was
a good opportunity for such investigation.6 AIDS Research and Treatment
It has been shown that, in the context of genotype-phe-
notype correlation with a large database, the linear model
without interactions provided also accurate predictions [6].
However, based on the full dataset results, we highlight
the importance of the two-way interactions terms for Least
Squares. Interactions between mutations are of scientiﬁc




applied on a relative small amount of data, provided good
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